Inorganic matrices: An answer to low drug solubility problem

Expert Opinion on Drug Delivery

Volumn 9, Issue 12, 2012, Pages 1559-1572

  Perioli, Luana ^a   Pagano, Cinzia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

BCS; Dissolution rate; Hydrotalcite; Inorganic matrices; Mesoporous materials; Solubility

Indexed keywords

BIOMATERIAL; CARBAMAZEPINE; COPOLYMER; CYCLODEXTRIN; FUROSEMIDE; INORGANIC MATRIX; MCM 41; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

BIOAVAILABILITY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STRUCTURE; HUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; SYSTEMATIC REVIEW;

BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; INORGANIC CHEMICALS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84869761210     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.733693     Document Type: Review

References (101)

1. Thomas VH, Bhattachar S, Hitchingham L, et al. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2006;2:591-608 (Pubitemid 46127071)
2. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49 (Pubitemid 32239479)
3. Kerns EH, Di L. Drug-like properties: concept, structure design and methods. Academic Press; London: 2008. p. 56-67
4. Benet LZ. Predicting DMPK of NMEs: what do we need in terms of science and tools? New England drug metabolism discussion group: Gerald Miwa Retirement Symposium; 2007
5. Ruddy SB, Callanan F. The insoluble solved. Drug Discov Dev 2011;14:24-5
6. Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 2011;11:2662-79
7. Bhattachar SN, Deschenes LA, Wesley JA. Solubility: it's not just for physical chemists. Drug Discov Today 2006;11:1012-18 (Pubitemid 44572881)
8. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001;46:75-87
9. Levich VG. Physicochemical hydrodynamics. Prentice-Hall; Englewood Cliffs, N.J: 1962
10. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 2006;321:1-11 (Pubitemid 44247428)
11. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010;7:1388-405
12. Sugano K, Okazaki A, Sugimoto S, et al. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet 2007;22:225-54
13. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a pratical perspective. Adv Drug Deliv Rev 2004;56:335-47 (Pubitemid 38201429)
14. Puri V, Dantuluri AK, Kumar M, et al. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci 2010;40:84-93
15. Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22 (Pubitemid 28080861)
16. Abrahamsson B, Albery T, Eriksson A, et al. Food effects on tablet disintegration. Eur J Pharm Sci 2004;22:165-72 (Pubitemid 38668681)
17. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999;36:233-54 (Pubitemid 29178760)
18. Mosharraf M, Nystrom C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 1995;122:35-47
19. Aleeva GN, Zhuravleva MV, Khafizyanova RK. The role of excipients in determining the pharmaceutical and therapeutic properties of medicinal agents. Pharm Chem J 2009;43:230-4
20. Amidon GL, Lennernäs H, Shah VP, et al. A Theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-19
21. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of the essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265-78 (Pubitemid 39037234)
22. Varma MVS, Khandavilli S, Ashokraj Y, et al. Biopharmaceutic Classification System: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab 2004;5:375-88 (Pubitemid 39276602)
23. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003;20:1917-25 (Pubitemid 38005521)
24. Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin On Drug Deliv 2005;2:419-33 (Pubitemid 41683218)
25. Coceani N, Magarotto L, Ceschia D, et al. Theoretical and experimental analysis of drug release from an ensemble of polymeric particles containing amorphous and nano-crystalline drug. Chem Eng Sci 2012;71:345-55
26. Cho E, Cho W, Ho Cha K, et al. Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives. Intl J Pharm 2010;396(1-2):91-8
27. Junghanns JAH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295-309
28. Murdande SB, Pikal MJ, Shanker RM. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 2010;99:1254-64
29. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068-75 (Pubitemid 350186132)
30. Yoshida T, Kurimoto I, Yoshihara K, et al. Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: evaluation of solid dispersion formulations. Int J Pharm 2012;428(1-2):18-24
31. Bahl D, Bogner RH. Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm Res 2006;23:2317-25 (Pubitemid 44511512)
32. Colombo I, G, Grassi M, Grassi Drug mechanochemical activation. 2009;98:3961-86
33. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2012;Available from: http://dx.doi.org/10.1016/j.ijpharm.2012.06.055
34. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev 2007;59:667-76 (Pubitemid 47285409)
35. Kohli K, Chopra S, Dhar D, et al. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today 2010;15:958-65
36. Müller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN-) versus drug nanocrystals. Int J Pharm 2006;317:82-9 (Pubitemid 43866342)
37. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48 (Pubitemid 46344627)
38. Heikkilä T, Salonen J, Tuura J, et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007;14:337-47 (Pubitemid 47265819)
39. Del Hoyo C. Layered double hydroxides and human health: an overview. Appl Clay Sci 2007;36:103-21
40. Choy JH, Choi SJ, Oh JM, et al. Clay minerals and layered double hydroxides for novel biological applications. Appl Clay Sci 2007;36:122-32
41. Tammaro L, Costantino U, Bolognese A, et al. Nanohybrids for controlled antibiotic release in topical applications. Int J Antimicrob Agents 2007;29:417-23 (Pubitemid 46349595)
42. Van Speybroeck M, Barillaro V, Thi TD, et al. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J Pharm Sci 2009;98:2648-58
43. Ambrogi V, Perioli L, Marmottini F, et al. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur J Pharm Sci 2007;32:216-22 (Pubitemid 47532714)
44. Sing SK, Everett DH, Haul AW, et al. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity. Pure Appl Chem 1985;57:603-19
45. Manzano M, Colilla M, Vallet-Reg̀ M. Drug delivery from ordered mesoporous matricers. Exp Opin 2009;6:1383-400
46. Meynen V, Cool P, Vansant EF. Verified syntheses of mesoporous materials. Micropor Mesopor Mater 2009;125:170-223
47. Kresge CT, Leonowicz ME, Roth WJ, et al. Ordered mesoporous molecular sieves synthesized by a liquid crystal template mechanism. Nature 1992;359:710-12 (Pubitemid 23589384)
48. Brühwiler D, Calzaferri G. Molecular sieves as host materials for supramolecular organization. Micropor Mesopor Mater 2004;72:1-23 (Pubitemid 38800858)
49. Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mater 2009;117:1-9
50. Ciesla U, Schüth F. Ordered mesoporous materials. Micropor Mesopor Mater 1999;27:131-49
51. Beck JS, Vartuli JC, Roth WJ, et al. A new family of mesoporous molecular sieves prepared with liquid crystal templates. J Am Chem Soc 1992;114:10834-43
52. Zhao D, Feng J, Huo Q, et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science 1998;279:548-52 (Pubitemid 28067280)
53. Zhao D, Feng J, Huo Q, et al. Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrotermally stable, mesoporous silica structures. J Am Chem Soc 1998;120:6024-36 (Pubitemid 28306987)
54. Celera EB, Kruk M, Zuzek Y, et al. Hydrothermal stability of SBA-15 and related ordered mesoporous silicas with plugged pores. Mater Chem 2006;16:2824-33 (Pubitemid 43993800)
55. Silvestre-Albero A, Jardim EO, Bruijn E, et al. Is there any microporosity in ordered mesoporous silicas? Langmuir 2009;25:939-43
56. Esparza JM, Ojeda ML, Campero A, et al. N2 sorption scanning behavior of SBA-15 porous substrates. Colloids Surf A Physicochem Eng Asp 2004;241:35-45 (Pubitemid 39090284)
57. Ambrogi V, Perioli L, Marmottini F, et al. Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Micropor Mesopor Mater 2008;113:445-52
58. Ambrogi V, Perioli L, Pagano C, et al. MCM-41 for furosemide dissolution improvement. Micropor Mesopor Mater 2012;147:343-9
59. Vadia N, Rajput S. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement. Eur J Pharm Sci 2012;45:8-18
60. Heikkilä T, Salonen J, Tuura J, et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007;14:337-47 (Pubitemid 47265819)
61. Sliwinska-Bartkowiak M, Dudziak G, Gras R, et al. Freezing behavior in porous glasses and MCM-41. Coll Surf A Physicochem Eng Aspects 2001;187:523-9 (Pubitemid 32619185)
62. Trifirò F, Vaccari A. Solid state supramolecular chemistry: two-and three-dimensional inorganic networks. In: Alberti M, Bein T, editors. Comprehensive supramolecular chemistry. Volume 7 Pergamon-Elsevier; Oxford: 1996. p. 1-46
63. Pucciariello R, Tammaro L, Villani V, et al. New nanohybrids of poly (Ô-caprolactone) and a modified Mg/Al hydrotalcite: mechanical and thermal properties. J Polymer Sci Part B Polymer physics 2007;45:945-54 (Pubitemid 46642318)
64. Miyata S. Anion-exchange properties of hydrotalcite-like compounds. Clays Clay Miner 1983;31:305-11
65. Costantino U, Ambrogi V, Nocchetti M, et al. Hydrotalcite-like compounds: versatile layered hosts of molecular anions with biological activity. Micropor Mesopor Mater 2008;107:149-60 (Pubitemid 350102825)
66. Nagaoka K, Jentys A, Lercher JA. Methane autothermal reforming with and without ethane over mono-and bimetal catalysts prepared from hydrotalcite precursors. J Catal 2005;229:185-96
67. Costantino U, Coletti N, Nocchetti M. Anion exchange of methyl orange into Zn-Al synthetic hydrotalcite and photophysical characterization of the intercalates obtained. Langmuir 1999;15:4454-60
68. Mohana D, Pittman CU. Arsenic removal from water/wastewater using adsorbents-A critical review. J Hazard Mater 2007;142:1-53
69. Carretero MI, Pozo M. Clay and non-clay minerals in the pharmaceutical and cosmetic industries Part II. Active ingredients. Appl Clay Sci 2010;47:171-81
70. Li Y, Hou WG, Shen S. Rheological behavior of aqueous suspensions containing cationic starch and aluminum magnesium hydrotalcite-like compound in the presence of different electrolytes. Colloids Surf A Physicochem Eng Aspects 2009;350:109-13
71. Costantino U, Nocchetti M. Layered double hydroxydes and their intercalation compounds in photochemistry and medicinal chemistry. In: Rives V, editor. Layered double hydroxides: present and future. Nova Science Publishers Inc; New York: 2001. p. 383-411
72. Aguzzi C, Cerezo P, Viseras C, et al. Use of clays as drug delivery systems: possibilites and limitations. Appl Clay Sci 2007;36:22-36 (Pubitemid 46404593)
73. Tamura H, Chiba J, Ito M, et al. Synthesis and characterization of hydrotalcite-ATP intercalates. Solid State Ion 2004;172:607-9
74. Xu ZP, Lu GQM. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem 2006;78:1771-9
75. Ambrogi V, Fardella G, Grandolini G, et al. Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents-I. Intercalation and in vitro release of ibuprofen. Int J Pharm 2001;220:23-32 (Pubitemid 32476838)
76. Choy JH, Jung JS, Oh JM, et al. Layered double hydroxide as an efficient drug reservoir for folate derivatives. Biomaterials 2004;25:3059-64
77. Ambrogi V, Perioli L, Ciarnelli V, et al. Effect of gliclazide immobilization into layered double hydroxide on drug release. Eur J Pharm Biopharm 2009;73:285-91
78. Del Arco M, Fernández A, Martín C, et al. Intercalation of mefenamic and meclofenamic acid anions in hydrotalcite-like matrixes. Appl Clay Sci 2007;36:133-40 (Pubitemid 46414159)
79. Perioli L, Posati T, Nocchetti M, et al. Intercalation and release of antiinflammatory drug diclofenac into nanosized ZnAl hydrotalcite-like compound. Appl Clay Sci 2011;53:374-8
80. Ambrogi V, Perioli L, Ricci M, et al. Eudragit and hydrotalcite-like anionic clay composite system for diclofenac colonic delivery. Micropor Mesopor Mater 2008;115:405-15
81. Posati T, Bellezza F, Tarpani L, et al. Selective internalization of ZnAl-HTlc nanoparticles in normal and tumor cells. A study of their potential use in cellular delivery. Appl Clay Sci 2012;55:62-9
82. Ambrogi V, Perioli L, Marmottini F, et al. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form. Eur J Pharm Biopharm 2007;66:253-9 (Pubitemid 46654767)
83. Choi G, Lee JH, Oh YJ, et al. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int J Pharm 2010;402:117-22
84. Bellezza F, Nocchetti M, Posati T, et al. Synthesis of colloidal dispersions of NiAl, ZnAl, NiCr, ZnCr, NiFe, and MgFe hydrotalcite-like nanoparticles. J Coll Int Sci 2012;376:20-7
85. Rossi C, Schoubben A, Ricci M, et al. Intercalation of the radical scavenger ferulic acid in hydrotalcite-like anionic clays. Int J Pharm 2005;295:47-55 (Pubitemid 40558788)
86. Perioli L, Ambrogi V, Bertini B, et al. Anionic clays for sunscreen agent safe use: photoprotection, photostability and prevention of their skin penetration. Eur J Pharm Biopharm 2006;62:185-93 (Pubitemid 43143271)
87. Perioli L, Ambrogi V, Rossi C, et al. Use of anionic clays for photoprotection and sunscreen photostability: hydrotalcites and phenylbenzimidazole sulfonic acid. J Phys Chem Sol 2006;67:1079-83 (Pubitemid 43850500)
88. Perioli L, Nocchetti M, Ambrogi V, et al. Sunscreen immobilization on ZnAl-hydrotalcite for new cosmetic formulations. Micropor Mesopor Mater 2008;107:180-9 (Pubitemid 350102826)
89. Perioli L, Ambrogi V, Giovagnoli S, et al. Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. AAPS Pharm Sci Tech 2007;8(3):E54. Available from: http://www. aapspharmscitech.org
90. Ambrogi V, Fardella G, Grandolini G, et al. Effect of hydrotalcite like-compounds on the aqueous solubility of some poorly water-soluble drugs. J Pharm Sci 2003;92:1407-18 (Pubitemid 36792754)
91. Perioli L, Ambrogi V, di Nauta L, et al. Effects of hydrotalcite-like nanostructured compounds on biopharmaceutical properties and release of BCS class II drugs: the case of flurbiprofen. Appl Clay Sci 2011;51:407-13
92. Ambrogi V, Fardella G, Grandolini G, et al. Intercalation compounds of hydrotalcite-like anionic clays with anti-inflammatory agents, II: uptake of diclofenac for a controlled release formulation. AAPS PharmSciTech 2002;2:1-6; article 26
93. Perioli L, Ambrogi V, Nocchetti M, et al. Preformulation studies on host-guest composites for oral administration of BCS class IV drugs: HTlc and furosemide. Appl Clay Sci 2011;53:696-703
94. Gené E, Calvet X, Morón A, et al. Recommendations for the use of anti-inflammatory drugs and indications for gastrointestinal protection in emergency departments. Emergencias 2009;21:295-300
95. Jobbagy M, Regazzoni AE. Dissolution of nano-size Mg-Al-Cl hydrotalcite in aqueous media. Appl Clay Sci 2011;51:366-9
96. Del Arco M, Cebadera E, Gutiérrez S, et al. Mg-Al layered double hydroxides with intercalated indomethacin: synthesis, characterization, and pharmacological study. J Pharm Sci 2004;93:1649-58 (Pubitemid 38725035)
97. del Arco M, Fernández A, Martín C, et al. Solubility and release of fenamates intercalated in layered double hydroxydes. Clay Miner 2008;43:255-65
98. Davis SS. Formulation strategies for absorption windows. Drug Discov Today 2005;10:249-57 (Pubitemid 40222218)
99. Granero GE, Longhi MR, Mora MJ, et al. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci 2010;99:2544-56
100. Brouwers J, Brewster ME, Augustijns PJ. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? Pharm Sci 2009;98:2549-72
101. Ambrogi V, Perioli L, Pagano C, et al. Use of SBA-15 for furosemide oral delivery enhancement. Eur J Pharm Sci 2012;46:43-8